sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Phenylketonuria
Conditions
Phenylketonuria
Trial Timeline
Oct 1, 2008 → Oct 1, 2009
NCT ID
NCT00789568About sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placebo
sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placebo is a phase 1 stage product being developed by BioMarin Pharmaceutical for Phenylketonuria. The current trial status is completed. This product is registered under clinical trial identifier NCT00789568. Target conditions include Phenylketonuria.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00789568 | Phase 1 | Completed |
Competing Products
20 competing products in Phenylketonuria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SYNB1934v1 + Placebo | Synlogic | Phase 3 | 69 |
| SYNB1618 + Placebo | Synlogic | Phase 1/2 | 33 |
| SYNB1618 + SYNB1934 | Synlogic | Phase 2 | 44 |
| Kuvan® | Merck | Phase 3 | 77 |
| Kuvan® | Merck | Approved | 85 |
| SAR444836 | Sanofi | Phase 1/2 | 40 |
| Kuvan | BioMarin Pharmaceutical | Pre-clinical | 20 |
| rAvPAL-PEG | BioMarin Pharmaceutical | Phase 2 | 49 |
| rAvPAL-PEG | BioMarin Pharmaceutical | Phase 2 | 49 |
| Sapropterin (Kuvan) | BioMarin Pharmaceutical | Pre-clinical | 20 |
| BMN 165 (rAvPAL-PEG) | BioMarin Pharmaceutical | Phase 2 | 49 |
| BMN 307 | BioMarin Pharmaceutical | Phase 1/2 | 38 |
| Sapropterin | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Sapropterin dihydrochloride + Placebo | BioMarin Pharmaceutical | Phase 3 | 74 |
| BMN165 20mg/day + BMN165 40mg/day + Placebo | BioMarin Pharmaceutical | Phase 3 | 74 |
| sapropterin dihydrochloride | BioMarin Pharmaceutical | Phase 3 | 74 |
| saproterin dihydrochloride | BioMarin Pharmaceutical | Approved | 82 |
| Pegvaliase | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Pegvaliase | BioMarin Pharmaceutical | Pre-clinical | 20 |
| sapropterin dihydrochloride | BioMarin Pharmaceutical | Phase 2 | 49 |